AUTERI, GIUSEPPE
 Distribuzione geografica
Continente #
NA - Nord America 464
AS - Asia 163
EU - Europa 129
SA - Sud America 49
AF - Africa 31
OC - Oceania 1
Totale 837
Nazione #
US - Stati Uniti d'America 455
SG - Singapore 91
CN - Cina 52
BR - Brasile 43
IE - Irlanda 42
IT - Italia 30
BE - Belgio 17
SN - Senegal 13
KR - Corea 12
CI - Costa d'Avorio 10
RU - Federazione Russa 8
FI - Finlandia 7
CA - Canada 6
CH - Svizzera 4
NG - Nigeria 4
AR - Argentina 3
AT - Austria 3
ES - Italia 3
GB - Regno Unito 3
UA - Ucraina 3
DE - Germania 2
FR - Francia 2
IN - India 2
MA - Marocco 2
MX - Messico 2
NL - Olanda 2
PL - Polonia 2
AU - Australia 1
BD - Bangladesh 1
CL - Cile 1
IQ - Iraq 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
LT - Lituania 1
PK - Pakistan 1
TR - Turchia 1
UY - Uruguay 1
VE - Venezuela 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 837
Città #
Santa Clara 94
Dallas 79
Houston 70
Singapore 67
Dublin 38
Chandler 31
Chicago 21
Hefei 18
Brussels 17
Ashburn 16
Boardman 14
Civitanova Marche 13
Dakar 13
Seoul 12
Beijing 11
Cambridge 11
Lawrence 11
Abidjan 10
Andover 10
Des Moines 9
Los Angeles 5
Turku 5
Abuja 4
Hebei 4
Saint Petersburg 4
Ann Arbor 3
Brooklyn 3
Nanjing 3
São Paulo 3
Toronto 3
Boston 2
Jandira 2
Lappeenranta 2
Messina 2
Mexico City 2
Montreal 2
Munich 2
Redwood City 2
Sassuolo 2
Seattle 2
Washington 2
Wilmington 2
Aci Sant'Antonio 1
Agadir 1
Amman 1
Amsterdam 1
Aracaju 1
Aracati 1
Atlanta 1
Baoding 1
Belo Horizonte 1
Bom Jesus do Galho 1
Brejo Santo 1
Brest 1
Buriti 1
Cabo Frio 1
Cametá 1
Campo Grande 1
Can Tho 1
Cerquilho 1
Charlotte 1
Charqueada 1
Columbus 1
Cranford 1
Dearborn 1
Durban 1
Eusébio 1
Fazenda Nova 1
Fresno 1
Gravatá 1
Guanhães 1
Guareí 1
Guaíra 1
Hangzhou 1
Itaquaquecetuba 1
Itu 1
Jacksonville 1
Jiaxing 1
Jundiaí 1
Kunming 1
Lagoa do Itaenga 1
Lahore 1
Leopoldina 1
London 1
Loveland 1
Maceió 1
Mairiporã 1
Manchester 1
Melbourne 1
Merlo 1
Milan 1
Montevideo 1
Moscow 1
Nairobi 1
Nanuque 1
Naples 1
Naviraí 1
Nhandeara 1
Nova Iguaçu 1
Orem 1
Totale 684
Nome #
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 133
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 62
Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis 62
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 62
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data 58
Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome 58
Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients 57
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study 55
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 55
Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronic-phase myelofibrosis 55
Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib 55
Determinants of Covid19 disease and of survival after Covid19 in MPN patients treated with ruxolitinib 54
Impact of comorbidities and body mass index on the outcome of polycythemia vera patients 54
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study 40
Totale 860
Categoria #
all - tutte 3.391
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.391


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202117 0 0 0 3 6 1 3 0 2 1 1 0
2021/202267 3 10 0 0 12 2 11 0 1 7 1 20
2022/2023117 11 0 7 1 9 23 2 26 23 0 7 8
2023/202486 6 30 4 4 4 13 7 1 0 1 10 6
2024/2025301 4 37 14 17 79 39 6 3 20 23 38 21
2025/2026181 41 36 93 11 0 0 0 0 0 0 0 0
Totale 860